Nav: Home

Eribulin in liposarcoma: Added benefit not proven

September 07, 2016

Eribulin (trade name: Halaven) has been approved since May 2016 for the treatment of adults with advanced liposarcoma. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether the drug offers an added benefit over the appropriate comparator therapy in these patients.

According to the findings, the dossier contained no data suitable for the assessment: In the only study of direct comparison, the dosage of the drug in the comparator arm was not in compliance with the approval. It was not ensured in an indirect comparison that the respective patient populations were sufficiently similar. An added benefit of eribulin is therefore not proven.

New therapeutic indication of eribulin

The Institute had assessed the added benefit of eribulin for women with advanced or metastatic breast cancer in two earlier dossier assessments (2012 and 2014). In May 2016, the approval of eribulin was expanded to treatment of unresectable liposarcoma, a type of cancer that develops in fat tissue, that cannot be surgically removed and that has already formed metastases. It is an option for adults who have already received chemotherapy with the drug anthracycline.

The appropriate comparator therapy specified by the Federal Joint Committee (G-BA) was antineoplastic drug treatment at the physician's discretion under consideration of the respective approval status of the drugs currently used and of the prior therapies.

Drug not used in compliance with the approval in the control arm

In its dossier, the drug manufacturer used one study of direct comparison that tested eribulin against dacarbazine. In the control arm, dacarbazine was not used in compliance with the approval, however: Instead of administration in combination with another drug (doxorubicin), dacarbazine was used as monotherapy, and a different dosage was used in the beginning of the treatment. The results of the study were therefore unsuitable to derive an added benefit.

Similarity of the study population not ensured

The latter was also true for the data from an indirect comparison: Here, the manufacturer analysed studies that compared either eribulin or trabectedin with dacarbazine. To be able to derive benefit or harm from such an indirect comparison, however, it has to be ensured that the study participants are sufficiently similar. This was not the case. It could therefore not be excluded that differences in the treatment results were caused by differences between the study populations and not by the different drugs used.

G-BA decides on the extent of added benefit

The dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the G-BA. After publication of the dossier assessment, the G-BA conducts a commenting procedure and makes a final decision on the extent of the added benefit.
An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website, published by IQWiG, provides easily understandable German-language information.

More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as subsequently published health information on If you would like to be informed when these documents are available, please send an e-mail to

Institute for Quality and Efficiency in Health Care

Related Comparator Therapy Articles:

Radiation therapy, macrophages improve efficacy of nanoparticle-delivered cancer therapy
Massachusetts General Hospital investigators report finding finding how appropriately timed radiation therapy can significantly improve the delivery of cancer nanomedicines by attracting macrophages to tumor blood vessels, which results in a transient 'burst' of nanoencapsulated drugs from capillaries into the tumor.
Lipid nanoparticles for gene therapy
Twenty-five years have passed since the publication of the first work on solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) as a system for delivering drugs.
Pet therapy can combat homesickness
The expression dog is man's best friend might have more weight in the case of first-year university students suffering from homesickness, according to a new UBC study.
On the path to controlled gene therapy
The ability to switch disease-causing genes on and off remains a dream for many physicians, research scientists and patients.
Transplantation and cell therapy
Key leaders in the field of cellular therapy will highlight new applications to potentially cure patients with blood diseases and infections on the occasion of the 5th Cell Therapy Day.
Benefit of extending anticoagulation therapy lost after discontinuation of therapy
Among patients with a first episode of pulmonary embolism (the obstruction of the pulmonary artery or a branch of it leading to the lungs by a blood clot) who received six months of anticoagulant treatment, an additional 18 months of treatment with warfarin reduced the risk of additional blood clots and major bleeding, however, the benefit was not maintained after discontinuation of anticoagulation therapy, according to a study in the July 7 issue of JAMA.
Japanese Society for Dialysis Therapy to publish Renal Replacement Therapy with BioMed Central
BioMed Central is pleased to partner with the Japanese Society for Dialysis Therapy in publishing the open-access journal Renal Replacement Therapy.
Can light therapy help the brain?
An innovative therapy that applies red and near-infrared light to the brain is now being tested at the Boston VA for Gulf War Illness, traumatic brain injury, and PTSD.
Not all EGFR mutations are the same when it comes to therapy for NSCLC
Certain rare epidermal growth factor receptor mutations are associated with tobacco smoking, worse prognosis and poor response to EGFR tyrosine kinase inhibitor therapy compared to the more common 'classical' EGFR mutations.
Clinical trial shows benefits of animal-assisted therapy in adult cancer patients undergoing complex cancer treatment with chemotherapy and radiation therapy
Therapy dogs may improve the emotional well-being of some cancer patients, according to results of a clinical study, the first to document the benefits of animal-assisted therapy in adult cancer patients.

Related Comparator Therapy Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...